Asmanex is an inhaled corticosteroid. Asmanex 220 mcg was approved on March 31, 2005, by the FDA for maintenance treatment of asthma as preventive therapy in patients 12 years of age and older.

NEW YORK (MarketWatch) -- Schering-Plough Corp. lifted 27 cents, or 1.5 percent, to $27.29 in premarket trade Thursday after the U.S. Food & Drug Administration approved the Asmanex Twisthaler 220 ...

ASMANEX, indicated for the maintenance treatment of asthma as prophylactic therapy in patients four years of age and older, is now available in pharmacies nationwide.

On March 30, the FDA approved mometasone furoate inhalation powder (Asmanex Twisthaler 220 µg, made by Schering-Plough Corp) for the first-line maintenance treatment of asthma as prophylactic ...

As with other corticosteroid inhalers, Asmanex has possible adverse effects including stunting a child's growth rate, causing oral fungal infections, and increasing users' risks of glaucoma or ...

Schering-Plough announced that the FDA has approved Asmanex Twisthaler 110 mcg (mometasone furoate inhalation powder) for the maintenance treatment of asthma as a preventive therapy in patients 4 to ...

Asmanex Twisthaler has been launched by Schering-Plough as therapy in the control and management of mild, moderate or severe persistent asthma in patients 12 years of age and older.

The 110mcg strength of Asmanex Twisthaler (mometasone furoate inhalation powder, from Schering-Plough), an inhaled corticosteroid, is now available for the maintenance treatment of asthma in ...

FDA has approved a new inhaler therapy for children with asthma called Asmanex Twisthaler 220 mcg to be taken only once daily . The oral inhalation treatment may take about 1 to 2 weeks or longer ...

The FDA has approved Asmanex Twisthaler (mometasone furoate inhalation powder, from Schering-Plough) 110 mcg for the maintenance treatment of asthma as a preventive therapy in patients 4-11 years ...